Welcome to the Oncology Brothers podcast! In this episode, we talked about the most recent developments in the world of myeloproliferative neoplasms (MPNs), including the exciting FDA approvals of ropeginterferon alfa-2b for essential thrombocythemia (ET) and rusfertide for polycythemia vera (PV).
The leading author Dr. John Mascarenhas, an MPN specialist from the Mount Sinai, New York, shared insights from the SURPASS-ET study, which paved the way for the official approval of ropeginterferon alfa-2b in ET. Dr. Mascarenhas discussed the study design, findings, and the implications of using ropeginterferon alfa-2b compared to traditional therapies like anagrelide and hydroxyurea.
Key topics covered in this episode included:
Overview of the SURPASS-ET study and its significance
Efficacy and tolerability of ropeginterferon alfa-2b in ET
Side effect profiles of ropeginterferon alfa-2b vs anagrelide
The importance of monitoring JAK2 allele burden and its clinical relevance
Considerations for using ropeginterferon alfa-2b in frontline therapy for select patients
Join us as we explore the evolving landscape of MPN treatment and the potential for disease modification with ropeginterferon alfa-2b. Don't forget to like, subscribe, and check out our other discussions on oncology topics!
Podden och tillhörande omslagsbild på den här sidan tillhör
Oncology Brothers. Innehållet i podden är skapat av Oncology Brothers och inte av,
eller tillsammans med, Poddtoppen.
